Chasing Cures. Delivering Hope™
Translating groundbreaking science and precision delivery into potentially life-changing medicines for people living with FTD and ALS.
AN UNMET MEDICAL NEED
Frontotemporal dementia (FTD) and other neurodegenerative diseases like Alzheimer’s disease and amyotrophic lateral sclerosis (ALS) are depriving people of the prime years of their lives and have a devastating impact on families and loved ones. Few to no treatments exist for many of these neurodegenerative diseases despite many decades of research.
Recent progress and successes in genetic medicine have demonstrated its great promise in treating previously untreatable, life-threating neurological diseases.
Our innovative, neuroanatomy-led approach is designed to maximize the therapeutic potential of gene therapy to potentially halt or potentially even reverse neurodegenerative diseases. We deliver our gene therapies directly to the central nervous system where we believe they will provide the most benefit to patients.
About Us
Join Us
Our Science
A Phase 1/2 open-label clinical study to evaluate the safety and preliminary efficacy of AVB-101 in people with a genetic sub-type of frontotemporal dementia (FTD-GRN) is now open for enrollment.